Literature DB >> 16257492

Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: variations with behavioral state and repeated ascorbate treatment.

G V Rebec1, S K Conroy, S J Barton.   

Abstract

Membrane and morphological abnormalities occur in the striatum of R6/2 transgenics, a widely used mouse model of Huntington's disease. To assess changes in behavior-related neuronal activity, we implanted micro-wire bundles in the striatum of symptomatic R6/2 mice and wild-type controls. Unit activity was recorded in an open-field arena once weekly for the next several weeks. For each recording session, firing rate was monitored before, during, and after a period of light anesthesia to assess the influence of behavioral arousal. Because low ascorbate in striatal extracellular fluid may contribute to Huntington's disease symptoms, all animals received an injection of either 300 mg/kg sodium ascorbate or vehicle for three consecutive days prior to each recording session. In R6/2 mice, regardless of treatment, striatal unit activity was significantly faster than in wild-type controls. The difference in mean (+/-S.E.M.) firing was most apparent during wakefulness (6.4+/-0.8 vs. 3.5+/-0.3 spikes/s) but also persisted during anesthesia (2.0+/-0.3 vs. 0.7+/-0.1 spikes/s). Assessment of treatment duration indicated that R6/2 mean waking discharge rate was significantly slower after three weeks than after one week of ascorbate treatment (3.1+/-0.6 vs. 10.2+/-2.7 spikes/s). Vehicle-treated R6/2s showed no such decline in striatal activity ruling out an age- or injection-related effect. Slow-scan voltammetry in separate animals confirmed that ascorbate-injections returned the level of striatal extracellular ascorbate in R6/2 mice to that of wild-type controls. Our results indicate that although striatal neurons modulate firing in relation to behavioral state, impulse activity is consistently elevated in transgenic relative to wild-type mice. Restoring extracellular ascorbate to the wild-type level reverses this effect suggesting a role for ascorbate in normalizing neuronal function in Huntington's disease striatum.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16257492     DOI: 10.1016/j.neuroscience.2005.08.062

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  53 in total

1.  Pallidal neuronal discharge in Huntington's disease: support for selective loss of striatal cells originating the indirect pathway.

Authors:  Philip A Starr; Gail A Kang; Susan Heath; Shoichi Shimamoto; Robert S Turner
Journal:  Exp Neurol       Date:  2008-02-14       Impact factor: 5.330

2.  Rescue of homeostatic regulation of striatal excitability and locomotor activity in a mouse model of Huntington's disease.

Authors:  Yumei Cao; David Bartolomé-Martín; Naama Rotem; Carlos Rozas; Shlomo S Dellal; Marcelo A Chacon; Bashkim Kadriu; Maria Gulinello; Kamran Khodakhah; Donald S Faber
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

Review 3.  The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.

Authors:  Ravi Chopra; Vikram G Shakkottai
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 4.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

5.  Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes.

Authors:  Ana María Estrada-Sánchez; George V Rebec
Journal:  Basal Ganglia       Date:  2012-07-01

6.  Cortical efferents lacking mutant huntingtin improve striatal neuronal activity and behavior in a conditional mouse model of Huntington's disease.

Authors:  Ana María Estrada-Sánchez; Courtney L Burroughs; Stephen Cavaliere; Scott J Barton; Shirley Chen; X William Yang; George V Rebec
Journal:  J Neurosci       Date:  2015-03-11       Impact factor: 6.167

7.  Dysregulated information processing by medium spiny neurons in striatum of freely behaving mouse models of Huntington's disease.

Authors:  Benjamin R Miller; Adam G Walker; Anand S Shah; Scott J Barton; George V Rebec
Journal:  J Neurophysiol       Date:  2008-07-30       Impact factor: 2.714

8.  Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models.

Authors:  Carlos Cepeda; Laurie Galvan; Sandra M Holley; Shilpa P Rao; Véronique M André; Elian P Botelho; Jane Y Chen; Joseph B Watson; Karl Deisseroth; Michael S Levine
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

Review 9.  Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms.

Authors:  Carlos Cepeda; Damian M Cummings; Véronique M André; Sandra M Holley; Michael S Levine
Journal:  ASN Neuro       Date:  2010-04-07       Impact factor: 4.146

10.  Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse.

Authors:  B R Miller; J L Dorner; M Shou; Y Sari; S J Barton; D R Sengelaub; R T Kennedy; G V Rebec
Journal:  Neuroscience       Date:  2008-02-15       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.